Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of ALKS 7119 in healthy male adults
NL-OMON43993Phase 1Active, not recruiting
- Sponsor
- Alkermes
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ALKS 7119 in Alzheimer's disease (AD) (2 arms), sponsored by Alkermes. Primary endpoints: Maximum observed plasma concentration, Time to maximum observed plasma concentration and 5 more. Started Jan 2016; status: active, not recruiting.
02
Drugs
ALKS 7119
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON43993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43993.